What is Regenxbio's EBITDA?

Regenxbio (RGNX) reported EBITDA of -$79.51M in Q1 2026.

How has Regenxbio's EBITDA changed year-over-year?

Regenxbio's EBITDA decreased by 594.4% year-over-year, from $16.08M to -$79.51M.

What is the long-term trend for Regenxbio's EBITDA?

Over 4 years (2021 to 2025), Regenxbio's EBITDA has grown at a -3.7% compound annual growth rate (CAGR), from $169.54M to -$145.58M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Regenxbio RGNX EBITDA

EBITDA at other companies

EyePoint, Inc. EYPT

-$86.59M-79.1%

Ultragenyx PharmaceuticalRARE

-$161M-20.1%

4D Molecular TherapeuticsFDMT

-$72.35M-37.6%

Solid Biosciences Inc.SLDB

-$56.91M-43.6%

Regeneron PharmaceuticalsREGN

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

−$83.4Mebit+

$3.9MDepreciation Depletion & Amortization

=-$79.51M

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's EBITDA?: Regenxbio (RGNX) reported EBITDA of -$79.51M in Q1 2026.
How has Regenxbio's EBITDA changed year-over-year?: Regenxbio's EBITDA decreased by 594.4% year-over-year, from $16.08M to -$79.51M.
What is the long-term trend for Regenxbio's EBITDA?: Over 4 years (2021 to 2025), Regenxbio's EBITDA has grown at a -3.7% compound annual growth rate (CAGR), from $169.54M to -$145.58M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.